Cell-Based Flu Vaccine May Be More Cost-Effective, Beneficial Among Children
A new study found that switching from a primary national plan of egg-based vaccines to cell-based vaccines for the flu would significantly reduce the impact of the seasonal virus at a lesser production and distribution cost.
Follow-Up Trials for Drugs with Accelerated Approval Often Miss FDA Deadline
Data suggest confirmatory trials conducted for drugs granted accelerated approval by the FDA have taken over 3 years on average to complete since 2012.
FDA Authorizes Merck and Ridgeback Biotherapeutics COVID-19 Oral Pill
In the space of 2 days, the FDA approved at-home oral treatments for patients with mild-to-moderate COVID-19, drug that were months in development. Today, it was Merck and Ridgeback Biotherapeutics’ turn.
2 Commerce Drive Cranbury, NJ 08512